Close

Hemispherx Biopharma (HEB) Reports Q3 Loss of $0.30/Share

Go back to Hemispherx Biopharma (HEB) Reports Q3 Loss of $0.30/Share

Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016

November 14, 2016 4:36 PM EST

PHILADELPHIA, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE: HEB) announces the filing of its Quarterly Report and its financial results for the nine months ended September 30, 2016. The net loss was approximately $6,329,000 or $(0.30) per share as compared to a net loss of $12,093,000 or ($0.62) per share for the same nine month period in 2015. Cash, cash equivalents and marketable securities were approximately $8,009,000 at September 30, 2016 as compared to $8,910,000 as of December 31, 2015.

Hemispherx Biopharma recently made changes to its senior management team and implemented austerity measures which included the reduction of executive compensation and elimination of... More

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016

November 10, 2016 8:30 AM EST

PHILADELPHIA, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the Company or Hemispherx) announced today that it anticipates filing its 2016 third quarter financial results for the quarter ended September 30, 2016 on Monday, November 14, 2016.  Hemispherx will host a conference call at 11:00 a.m. Eastern Standard Time (EST) on Tuesday, November 15, 2016 to provide a general business update. Hemispherx will respond to various stockholder questions submitted prior to the call. 

An audio replay of the conference call will be available on the Companys website approximately one hour following the conclusion of the... More